Roche's Ventana Medical Systems is building a new distribution center in Arizona and plans to generate additional jobs in the process.
GenomeDx Biosciences bagged Medicare coverage for its postoperative prostate cancer diagnostic, putting its test in the hands of more patients and helping the company gain ground in a crowded market. Read more >>
POPULAR COMMENT THREADS
More than a few presentations at the JP Morgan Healthcare conference this week sought to address the future of next-generation sequencing, particularly with the huge waves of related news. Foundation Medicine sold half its company to Roche for up to $1.2 billion and NantHealth is already being used in most cancer centers to guide treatment with a whopping $1.5 billion already spent to get it there and another $800 million raised in the last 6 months. Read more >>
Sequenom is teaming up with Cypher Genomics to develop a noninvasive prenatal test using the company's advanced genome interpretation screening technology, eyeing a bigger share of an increasingly competitive market.
Roche's Ventana Medical Systems has submitted its companion diagnostic test for ALK1-positive lung cancer for FDA approval, inching the company closer to full regulatory approval for the product and helping it gain ground in a fiercely competitive cancer diagnostics market.
Alongside the launch of a next generation sequencing-based oncology assay, Silicon Valley Biosystems is also rolling out a new name to reflect its mission of providing practical genetic information to patients.
Abbott Laboratories' diagnostics unit charted sizable gains in 2014, and the company is continuing its upward momentum in the new year with an exclusive licensing deal with the Institut Curie.
Myriad Genetics is teaming up with the Institut Pasteur for a research project to address the growing tuberculosis (TB) epidemic, continuing the company's diagnostics winning streak and expanding its global footprint.
From Our Sister Sites
A loose hair has contributed to the nationwide shortage of saline solution, as Hospira recalls another lot of the commonly used product.
The ripple effects from last week's Teva v. Sandoz ruling have begun. The U.S. Supreme Court sent three patent fights back to a lower court in light of that ruling, which ordered the Federal Circuit Court to defer to district-level findings on patent claims unless a "clear error" had been made.